170 related articles for article (PubMed ID: 21915711)
41. Farnesyltransferase inhibitor BMS-214662 induces apoptosis in myeloma cells through PUMA up-regulation, Bax and Bak activation, and Mcl-1 elimination.
Gómez-Benito M; Marzo I; Anel A; Naval J
Mol Pharmacol; 2005 Jun; 67(6):1991-8. PubMed ID: 15738311
[TBL] [Abstract][Full Text] [Related]
42. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
43. Topoisomerase II{alpha}-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin.
Yan T; Deng S; Metzger A; Gödtel-Armbrust U; Porter AC; Wojnowski L
Mol Cancer Ther; 2009 May; 8(5):1075-85. PubMed ID: 19417146
[TBL] [Abstract][Full Text] [Related]
44. M2, a novel anthracenedione, elicits a potent DNA damage response that can be subverted through checkpoint kinase inhibition to generate mitotic catastrophe.
Evison BJ; Pastuovic M; Bilardi RA; Forrest RA; Pumuye PP; Sleebs BE; Watson KG; Phillips DR; Cutts SM
Biochem Pharmacol; 2011 Dec; 82(11):1604-18. PubMed ID: 21889927
[TBL] [Abstract][Full Text] [Related]
45. The E3 ubiquitin-ligase Bmi1/Ring1A controls the proteasomal degradation of Top2alpha cleavage complex - a potentially new drug target.
Alchanati I; Teicher C; Cohen G; Shemesh V; Barr HM; Nakache P; Ben-Avraham D; Idelevich A; Angel I; Livnah N; Tuvia S; Reiss Y; Taglicht D; Erez O
PLoS One; 2009 Dec; 4(12):e8104. PubMed ID: 19956605
[TBL] [Abstract][Full Text] [Related]
46. A tagging-via-substrate approach to detect the farnesylated proteome using two-dimensional electrophoresis coupled with Western blotting.
Onono FO; Morgan MA; Spielmann HP; Andres DA; Subramanian T; Ganser A; Reuter CW
Mol Cell Proteomics; 2010 Apr; 9(4):742-51. PubMed ID: 20103566
[TBL] [Abstract][Full Text] [Related]
47. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
[TBL] [Abstract][Full Text] [Related]
48. Apoptotic and cytostatic farnesyltransferase inhibitors have distinct pharmacology and efficacy profiles in tumor models.
Manne V; Lee FY; Bol DK; Gullo-Brown J; Fairchild CR; Lombardo LJ; Smykla RA; Vite GD; Wen ML; Yu C; Wong TW; Hunt JT
Cancer Res; 2004 Jun; 64(11):3974-80. PubMed ID: 15173010
[TBL] [Abstract][Full Text] [Related]
49. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
Caraglia M; Marra M; Leonetti C; Meo G; D'Alessandro AM; Baldi A; Santini D; Tonini G; Bertieri R; Zupi G; Budillon A; Abbruzzese A
J Cell Physiol; 2007 May; 211(2):533-43. PubMed ID: 17192846
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design.
Lerner EC; Hamilton AD; Sebti SM
Anticancer Drug Des; 1997 Jun; 12(4):229-38. PubMed ID: 9199657
[TBL] [Abstract][Full Text] [Related]
51. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
[TBL] [Abstract][Full Text] [Related]
52. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
Peters DG; Hoover RR; Gerlach MJ; Koh EY; Zhang H; Choe K; Kirschmeier P; Bishop WR; Daley GQ
Blood; 2001 Mar; 97(5):1404-12. PubMed ID: 11222387
[TBL] [Abstract][Full Text] [Related]
53. TLN-4601, a novel anticancer agent, inhibits Ras signaling post Ras prenylation and before MEK activation.
Boufaied N; Wioland MA; Falardeau P; Gourdeau H
Anticancer Drugs; 2010 Jun; 21(5):543-52. PubMed ID: 20220516
[TBL] [Abstract][Full Text] [Related]
54. Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma.
Wei BR; Michael HT; Halsey CH; Peer CJ; Adhikari A; Dwyer JE; Hoover SB; El Meskini R; Kozlov S; Weaver Ohler Z; Figg WD; Merlino G; Simpson RM
Pigment Cell Melanoma Res; 2016 Nov; 29(6):643-655. PubMed ID: 27463366
[TBL] [Abstract][Full Text] [Related]
55. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines.
Miranda MB; McGuire TF; Johnson DE
Leukemia; 2002 Apr; 16(4):683-92. PubMed ID: 11960350
[TBL] [Abstract][Full Text] [Related]
56. Simvastatin interacts synergistically with tipifarnib to induce apoptosis in leukemia cells through the disruption of RAS membrane localization and ERK pathway inhibition.
Ahmed TA; Hayslip J; Leggas M
Leuk Res; 2014 Nov; 38(11):1350-7. PubMed ID: 25262449
[TBL] [Abstract][Full Text] [Related]
57. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor.
Rose WC; Lee FY; Fairchild CR; Lynch M; Monticello T; Kramer RA; Manne V
Cancer Res; 2001 Oct; 61(20):7507-17. PubMed ID: 11606387
[TBL] [Abstract][Full Text] [Related]
58. Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions.
Okamoto S; Jiang Y; Kawamura K; Shingyoji M; Tada Y; Sekine I; Takiguchi Y; Tatsumi K; Kobayashi H; Shimada H; Hiroshima K; Tagawa M
Cell Death Dis; 2014 Nov; 5(11):e1517. PubMed ID: 25393473
[TBL] [Abstract][Full Text] [Related]
59. Propofol suppresses cell viability, cell cycle progression and motility and induces cell apoptosis of ovarian cancer cells through suppressing MEK/ERK signaling via targeting circVPS13C/miR-145 axis.
Lu H; Zheng G; Gao X; Chen C; Zhou M; Zhang L
J Ovarian Res; 2021 Feb; 14(1):30. PubMed ID: 33563314
[TBL] [Abstract][Full Text] [Related]
60. Regulation of death induction and chemosensitizing action of 3-bromopyruvate in myeloid leukemia cells: energy depletion, oxidative stress, and protein kinase activity modulation.
Calviño E; Estañ MC; Sánchez-Martín C; Brea R; de Blas E; Boyano-Adánez Mdel C; Rial E; Aller P
J Pharmacol Exp Ther; 2014 Feb; 348(2):324-35. PubMed ID: 24307199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
